Labiotech: Why a US Presence Can Help European Biotechs Get Ahead
Patricia Zilliox, CEO of Eyevensys, discusses building the company’s presence in the US.
Patricia Zilliox, CEO of Eyevensys, discusses building the company’s presence in the US.
Patricia Zilliox, CEO of Eyevensys speaks about raising €27M to fund the launch of a phase II trial for its lead candidate, a non-viral gene therapy for an eye condition called uveitis that can lead to blindness.
Patricia Zilliox, CEO of Eyevensys discusses closing a $30 million in Series B financing intended for development of EYS606 for the treatment of chronic noninfectious uveitis.
Patricia Zilliox, CEO of Eyevensys discusses next steps for the company after completing a series B financing round.
Patricia Zilliox, CEO of Eyevensys gives insight on how Eyevensys plans to use the $30M funding raised from its Series B round.
In this interview, Patricia Zilliox, CEO of Eyevensys discusses its innovative non-viral gene therapy platform, with the aim of treating ocular diseases.